Discovery of potential pancreatic cholesterol esterase inhibitors using pharmacophore modelling, virtual screening, and optimization studies

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 26, Issue 4, 2011, Pages 535-545

  John, Shalini ^a   Thangapandian, Sundarapandian ^a   Sakkiah, Sugunadevi ^a   Lee, Keun Woo ^a  

^a Gyeongsang National University   (South Korea)

Author keywords

Common feature pharmacophore; Molecular docking; Optimization; Pancreatic cholesterol esterase; Virtual screening

Indexed keywords

CD 10645; CHOLESTEROL ESTERASE; ENZYME INHIBITOR; GK 03167; NCI 0040784; SEW 00846; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; DATA BASE; ENZYME ACTIVE SITE; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DOCKING; PHARMACOPHORE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SCREENING; STRUCTURE ANALYSIS;

DRUG DISCOVERY; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PANCREAS; STEREOISOMERISM; STEROL ESTERASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79959910842     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2010.535795     Document Type: Article

References (44)

1. Wang, C.S., Hartsuck, J.A. Bile salt-activated lipase. A multiple function lipolytic enzyme. Biochim. Biophys. Acta 1993, 1166, 1-19.
2. Lombardo, D. Bile salt-dependent lipase: its pathophysiological implications. Biochim. Biophys. Acta 2001, 1533, 1-28. (Pubitemid 32763262)
3. Wang, C.S., Martindale, M.E., King, M.M., Tang, J. Bile-saltactivated lipase: effect on kitten growth rate. Am. J. Clin. Nutr. 1989, 49, 457-463. (Pubitemid 19107257)
4. Howles, P.N., Stemmerman, G.N., Fenoglio-Preiser, C.M., Hui, D.Y. Carboxyl ester lipase activity in milk prevents fat-derived intestinal injury in neonatal mice. Am. J. Physiol. 1999, 277, G653-G661.
5. Howles, P.N., Carter, C.P., Hui, D.Y. Dietary free and esterified cholesterol absorption in cholesterol esterase (bile salt-stimulated lipase) gene-targeted mice. J. Biol. Chem. 1996, 271, 7196-7202.
6. Brodt-Eppley, J., White, P., Jenkins, S., Hui, D.Y. Plasma cholesterol esterase level is a determinant for an atherogenic lipoprotein profile in normolipidemic human subjects. Biochim. Biophys. Acta 1995, 1272, 69-72.
7. Fält, H., Hernell, O., Bläckberg, L. Does bile salt-stimulated lipase affect cholesterol uptake when bound to rat intestinal mucosa in vitro? Pediatr. Res. 2002, 52, 509-515.
8. Lin, G., Liao, W.C., Chiou, S.Y. Quantitative structure-activity relationships for the pre-steady-state inhibition of cholesterol esterase by 4-nitrophenyl-N-substituted carbamates. Bioorg. Med. Chem. 2000, 8, 2601-2607.
9. Pietsch, M., Gutschow, M. Alternate substrate inhibition of cholesterol esterase by thieno[2,3-d][1,3]oxazin-4-ones. J. Biol. Chem. 2002, 277, 24006-24013. (Pubitemid 34951912)
10. Terzyan, S., Wang, C.S., Downs, D., Hunter, B., Zhang, X.C. Crystal structure of the catalytic domain of human bile salt activated lipase. Protein Sci. 2000, 9, 1783-1790.
11. Lin, G., Shieh, C.T., Tsai, Y.C., Hwang, C.I., Lu, C.P., Chen, G.H. Structure-reactivity probes for active site shapes of cholesterol esterase by carbamate inhibitors. Biochim. Biophys. Acta 1999, 1431, 500-511. (Pubitemid 29232003)
12. Feaster, S.R., Quinn, D.M. Mechanism-based inhibitors of mammalian cholesterol esterase. Meth. Enzymol. 1997, 286, 231-252. (Pubitemid 27408195)
13. Feaster, S.R., Lee, K., Baker, N., Hui, D.Y., Quinn, D.M. Molecular recognition by cholesterol esterase of active site ligands: structure- reactivity effects for inhibition by aryl carbamates and subsequent carbamyl enzyme turnover. Biochemistry 1996, 35, 16723-16734. (Pubitemid 27020517)
14. Tew, D.G., Boyd, H.F., Ashman, S., Theobald, C., Leach, C.A. Mechanism of inhibition of LDL phospholipase A2 by monocyclicbeta- lactams. Burst kinetics and the effect of stereochemistry. Biochemistry 1998, 37, 10087-10093. (Pubitemid 28366362)
15. Chiou, S.Y., Lai, C.Y., Lin, L.Y., Lin, G. Probing stereoselective inhibition of the acyl binding site of cholesterol esterase with four diastereomers of 2?-N-alpha-methylbenzylcarbamyl-1,1?-bi-2- naphthol. BMC Biochem. 2005, 6, 17.
16. Krantz, A. A classification of enzyme inhibitors. Bioorg. Med. Chem. Lett. 1992, 2, 1327-1334.
17. Leung, D., Abbenante, G., Fairlie, D.P. Protease inhibitors: current status and future prospects. J. Med. Chem. 2000, 43, 305-341. (Pubitemid 30102072)
18. Martyn, D.C., Moore, M.J., Abell, A.D. Succinimide and saccharinbased enzyme-activated inhibitors of serine proteases. Curr. Pharm. Des. 1999, 5, 405-415. (Pubitemid 29319186)
19. Neumann, U., Gütschow, M. N-(Sulfonyloxy)phthalimides and analogues are potent inactivators of serine proteases. J. Biol. Chem. 1994, 269, 21561-21567. (Pubitemid 24274789)
20. Hlasta, D.J., Pagini, E.D. Human leukocyte elastase inhibitors. Annu. Rep. Med. Chem. 1994, 29, 195-204.
21. Powers, J.C., Odake, S., Oleksyszyn, J., Hori, H., Ueda, T., Boduszek, B., Kam, C. Proteases-structures, mechanism and inhibitors. Agents Actions Suppl. 1993, 42, 3-18.
22. Krantz, A., Spencer, R.W., Tam, T.F., Liak, T.J., Copp, L.J., Thomas, E.M., Rafferty, S.P. Design and synthesis of 4H-3,1- benzoxazin-4-ones as potent alternate substrate inhibitors of human leukocyte elastase. J. Med. Chem. 1990, 33, 464-479. (Pubitemid 20047560)
23. Deck, L.M., Baca, M.L., Salas, S.L., Hunsaker, L.A., Vander Jagt, D.L. 3-Alkyl-6-chloro-2-pyrones: selective inhibitors of pancreatic cholesterol esterase. J. Med. Chem. 1999, 42, 4250-4256. (Pubitemid 29483042)
24. Lin, G., Shieh, C.T., Ho, H.C., Chouhwang, J.Y., Lin, W.Y., Lu, C.P. Structure-reactivity relationships for the inhibition mechanism at the second alkyl-chain-binding site of cholesterol esterase and lipase. Biochemistry 1999, 38, 9971-9981.
25. Heynekamp, J.J., Hunsaker, L.A., Vander Jagt, T.A., Royer, R.E., Deck, L.M., Vander Jagt, D.L. Isocoumarin-based inhibitors of pancreatic cholesterol esterase. Bioorg. Med. Chem. 2008, 16, 5285-5294. (Pubitemid 351625873)
26. Bharatham, N., Bharatham, K., Lee, K.W. Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors. J. Mol. Graph. Model. 2007, 25, 813-823. (Pubitemid 46216116)
27. Pietsch, M., Gütschow, M. Synthesis of tricyclic 1,3-oxazin-4-ones and kinetic analysis of cholesterol esterase and acetylcholinesterase inhibition. J. Med. Chem. 2005, 48, 8270-8288. (Pubitemid 43033318)
28. Sakai, K., Watanabe, K., Masuda, K., Tsuji, M., Hasumi, K., Endo, A. Isolation, characterization and biological activities of novel triprenyl phenols as pancreatic cholesterol esterase inhibitors produced by Stachybotrys sp. F-1839. J. Antibiot. 1995, 48, 447-456.
29. Eilfeld, A., González Tanarro, C.M., Frizler, M., Sieler, J., Schulze, B., Gütschow, M. Synthesis and elastase-inhibiting activity of 2-pyridinyl-isothiazol-3(2H)-one 1,1-dioxides. Bioorg. Med. Chem. 2008, 16, 8127-8135.
30. Guner, O.F., Henry, D.R. Phamacophore Perception, Development, and Use in Drug Design. La Jolla, CA: International University Line, 2000, pp. 193-210.
31. Thangapandian, S., John, S., Sakkiah, S., Lee, K.W. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design. Eur. J. Med. Chem. 2010, 45, 4409-4417.
32. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46, 3-26. (Pubitemid 33653411)
33. Walters, W.P., Murcko, M.A. Prediction of 'drug-likeness'. Adv. Drug Deliv. Rev. 2002, 54, 255-271.
34. John, S., Thangapandian, S., Sakkiah, S., Lee, K.W. Identification of potent virtual leads to design novel indoleamine 2,3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies. Eur. J. Med. Chem. 2010, 45, 4004-4012.
35. Jones, G., Willett, P., Glen, R.C., Leach, A.R., Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748. (Pubitemid 27170693)
36. Manoj, K.A., Krishna, K.I., Lalitha, G. Docking of phosphonate and trehalose analog inhibitors into M. tuberculosis mycolyltransferase Ag85C: comparison of the two scoring fitness functions GoldScore and ChemScore, in the GOLD software. Bioinformation 2007, 1, 339-350.
37. Marcel, L.V., Jason, C.C., Michael, J.H., Christopher, W.M., Richard, D.T. Improved protein-ligand docking using GOLD. Proteins: Struct. Funct. Genet. 2003, 52, 609-623.
38. Wallace, A.C., Laskowski, R.A., Thornton, J.M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8, 127-134.
39. Böhm, H.J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput. Aided Mol. Des. 1994, 8, 243-256.
40. Krisztina, B., Thomas, S., Johann, G. Structure and reaction based evaluation of synthetic accessibility. J. Comput. Aided Mol. Des. 2007, 21, 311-325.
41. Andrea, Z., Krisztina, B., Thomas, S., Achim, H., Christof, H.S., Johann, G., Holger, C., Christian, L., Jorg, D., Juri, P., Matthias, R. Second-generation de novo design: a view from a medicinal chemist perspective. J. Comput. Aided Mol. Des. 2009, 23, 593-602.
42. Sheng, Y.Y. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov. Today 2010, 15, 444-450.
43. Wagner, A.B. SciFinder Scholar 2006: an empirical analysis of research topic query processing. J. Chem. Inf. Model. 2006, 46, 767-774.
44. Wang, Y., Bolton, E., Dracheva, S., Karapetyan, K., Shoemaker, B.A., Suzek, T.O., Wang, J., Xiao, J., Zhang, J., Bryant, S.H. An overview of the PubChem BioAssay resource. Nucleic Acids Res. 2010, 38, D255-D266.